Benjamin R. Wheeler serves as Chief Financial Officer at Myriad Genetics Inc., a precision medicine company specializing in genetic testing and oncology solutions. With over 20 years of experience in finance and strategic leadership within the healthcare and life sciences industries, Wheeler oversees all financial operations, including capital allocation, investor relations, treasury management, and financial planning. His strategic oversight has been instrumental in driving Myriad's growth amid evolving market dynamics and regulatory landscapes in genetic diagnostics. Prior to joining Myriad in 2020, Wheeler held progressive finance roles at PerkinElmer, Inc., where he served as Vice President of Finance for the Discovery & Analytical Solutions division, managing a $1.5 billion portfolio and leading financial integrations post-acquisitions. Earlier in his career, he worked at Deloitte Consulting and Baxter International, honing expertise in mergers and acquisitions, operational efficiency, and global financial strategy. Wheeler holds a Bachelor of Science in Finance from the University of Utah and an MBA from Northwestern University's Kellogg School of Management. Under Wheeler's leadership, Myriad Genetics has strengthened its balance sheet, achieving significant cost optimizations and supporting key product launches like the myRisk Hereditary Cancer Test expansions. His achievements include navigating the company through the COVID-19 pandemic with resilient financial performance, securing strategic partnerships, and enhancing shareholder value, positioning Myriad for sustained innovation in personalized medicine.